美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎的临床观察

发布时间：2018-04-27 04:02

本文选题：美沙拉嗪 + 康复新液　；参考：《中国药房》2017年29期

【摘要】：目的:观察美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎(UC)的临床疗效及安全性。方法:选取2012年3月-2014年8月在我院消化内科治疗的活动期UC患者120例,按照随机数字表法分为观察组和对照组,各60例。两组患者均给予活动期UC常规治疗,对照组患者在此基础上口服美沙拉嗪肠溶片1 g,tid;观察组患者在对照组的基础上加用康复新液30 mL加入生理盐水150 mL稀释后灌肠,qd。两组患者均治疗30 d。观察两组患者治疗前后血清肿瘤坏死因子(TNF)-α、白细胞介素1(IL-1)、IL-8、IL-10、超氧化物歧化酶(SOD)、一氧化氮(NO)、过氧化脂质(LPO)水平,比较两组患者临床疗效、复发率、肠镜疗效及不良反应发生情况。结果:治疗前,两组患者血清TNF-α、IL-1、IL-8、IL-10、SOD、NO、LPO水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者血清TNF-α、IL-1、IL-8、NO、LPO水平均明显降低,血清IL-10、SOD水平明显升高;且观察组患者血清TNF-α、IL-1、IL-8、NO、LPO水平明显低于对照组,IL-10、SOD水平明显高于对照组,差异均有统计学意义(P0.05)。观察组患者临床有效率为83.3%,复发率为11.7%,肠镜有效率为88.3%,显著优于对照组的66.7%、30.0%、70.0%,差异均有统计学意义(P0.05)。两组患者总不良反应发生率比较,差异无统计学意义(P0.05)。结论:美沙拉嗪联合康复新液保留灌肠可有效减轻活动期UC患者炎症反应及氧自由基损伤,且安全性较高。
[Abstract]:Objective: to observe the clinical efficacy and safety of mesalazine combined with Kangfuxin liquid retention enema in the treatment of active ulcerative colitis. Methods: 120 active UC patients treated in our hospital from March 2012 to August 2014 were randomly divided into observation group and control group with 60 cases each. The patients in the two groups were given routine treatment of active UC, the patients in the control group were given 1 g of mesalazine enteric coated tablets on this basis, and the patients in the observation group were treated with 30 mL of rehabilitation solution and 150 mL of normal saline on the basis of the control group, and the patients in the observation group were enema QD after diluted with 150 mL of normal saline. Both groups were treated for 30 days. The serum levels of TNF- 伪, IL-8 and IL-10, SOD, no, LPO were observed before and after treatment. The clinical efficacy, recurrence rate, endoscopy effect and adverse reaction were compared between the two groups. Results: before treatment, there was no significant difference between the two groups in the level of serum TNF- 伪, IL-8, IL-10, SOD, NOPO and LPO levels (P 0.05). After treatment, the serum levels of TNF- 伪, IL-1, IL-8, NOP- LPO and IL-10 / SOD in the two groups were significantly lower than those in the control group, and the levels of TNF- 伪, IL-1-, IL-8, IL-8, NOLPO in the patients in the observation group were significantly lower than those in the control group (P 0.05). The clinical effective rate of the observation group was 83.3%, the recurrence rate was 11.7 and the effective rate of enteroscopy was 88.30.This was significantly better than that of the control group (66.7%, 30.0%), and the difference was statistically significant (P 0.05). There was no significant difference in the incidence of total adverse reactions between the two groups (P 0.05). Conclusion: mesalazine combined with Kangkangxin solution can effectively reduce inflammatory reaction and oxygen free radical injury in patients with active UC, and the safety is higher.
【作者单位】：广元市第三人民医院消化内科;
【分类号】：R574.62

【相似文献】